INBPOTCPharmaceutical PreparationsFiscal year ends June 30

INTEGRATED BIOPHARMA INC

Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 25, 2026

$0.18+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $5.59M
P/E (TTM): –
Dividend yield: –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Integrated Biopharma reports no long-term debt line

Its balance sheet in XBRL does not include long-term debt, so totals and interest cost cannot be shown.

Bond issues

Individual notes and bonds outstanding

Bond-level data is not connected yet

Coupon, maturity and amount of each note will come from the debt footnote in Integrated Biopharma's annual report. Trading prices and yields need FINRA TRACE data.

Where these numbers come from

Parsed from the XBRL in Integrated Biopharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is INBP.

Revenue growth-19.3% · median 17.8%

Gross margin1.8% · median 90.7%

Operating margin-6.2% · median -93.1%

Net margin-6.5% · median -80.6%

Company	Revenue	Growth
BFRI	$46.18M	+17.8%
INBP	$43.87M	-19.3%
LXRX	$41.47M	-29.0%
JAGX	$27.82M	+135.5%
BHST	–	–
PRE	–	–

Company

Next earnings (est.): Nov 9, 2026, during market hours
Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: June 30
Employees: 134
Held by institutions: 0.1%
Auditor: CBIZ CPAs P.C.
SEC CIK: 1016504

Advertisement
300 × 250